Who makes Paxlovid 25 day dosing?

Paxlovid 25 day dosing is developed by Kanecia Obie Zimmerman.

What development phase is Paxlovid 25 day dosing in?

Paxlovid 25 day dosing is in Phase 2.

Last reviewed 2026-04-19 · How we verify

Paxlovid 25 day dosing

Kanecia Obie Zimmerman · Phase 2 active Small molecule

At a glance

Generic name	Paxlovid 25 day dosing
Sponsor	Kanecia Obie Zimmerman
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms (PHASE2)
RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Paxlovid 25 day dosing CI brief — competitive landscape report
Paxlovid 25 day dosing updates RSS · CI watch RSS
Kanecia Obie Zimmerman portfolio CI